Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors

Autor:	Kiyohiko Nakai, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, N. Sato, Takahiro Ebata, Kazuo Tamura, Takafumi Koyama, Michiyasu Inatani, Noboru Yamamoto, Shunsuke Kondo, Toshio Shimizu, Shigehisa Kitano
Rok vydání:	2018
Předmět:	Oncology medicine.medical_specialty Atezolizumab business.industry Internal medicine medicine Hematology business Phase i study
Zdroj:	Annals of Oncology. 29:viii138-viii139
ISSN:	0923-7534
DOI:	10.1093/annonc/mdy279.411
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::87164d89d35f7ec258d9e25d761b2ad2 https://doi.org/10.1093/annonc/mdy279.411 Zobrazit plný text záznamu